RT Book, Section
A1 Jenkins, Sasha
A1 Cotes, Maren
A1 Zwald, Fiona
A2 Avram, Marc R.
A2 Avram, Mathew M.
A2 Ratner, Désirée
SR Print(0)
ID 1175094650
T1 Skin Cancer in the Organ Transplant Patient
T2 Procedural Dermatology
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071795067
LK dermatology.mhmedical.com/content.aspx?aid=1175094650
RD 2024/04/23
AB Advances  in  the  management  of  solid  organ  transplantation  recipients  (OTR)  have  led  to  improved  overall  survival.  However,  patients  face  many  consequences  of  being  on  long-term  immunosuppression,  including  an  increased  risk  of  developing  premalignant  and  malignant  skin  cancers.  This  is  likely  to  pose  an  increasing  challenge  to  dermatologists,  as  the  number  of  patients  receiving  a  solid  organ  transplant  continues  to  grow  and  the  life  expectancy  of  these  patients  continues  to  increase.  Skin  cancers  are  the  most  common  malignancy  posttransplantation,  comprising  almost  40%  of  posttransplant  malignancies,  and  tend  to  behave  more  aggressively  than  in  nontransplant  patients.1  The  increased  risk  of  skin  cancer  impacts  patient  morbidity  and  quality  of  life  post  transplantation,  and  management  of  such  cases  places  a  significant  burden  on  diminishing  health  care  resources.